Literature DB >> 30368418

A Novel EML6-ALK FBXO11-ALK Double Fusion Variant in Lung Adenocarcinoma and Response to Crizotinib.

Hao Lin1, Guoqiang Ren2, Xiaohua Liang3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30368418     DOI： 10.1016/j.jtho.2018.07.011

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  4 in total

1.  Clinicopathological Characteristics and Molecular Phenotypes of Primary Hepatic Lymphoma.

Authors:  Ai-Yan Xing; Xin-Zhe Dong; Liu-Qing Zhu; Long Liu; Dong Sun; Sen Guo
Journal:  Front Oncol       Date:  2022-06-27       Impact factor: 5.738

2.  Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively.

Authors:  Hong Tao; Zhe Liu; Jing Mu; Fei Gai; Zhan Huang; Liang Shi
Journal:  Diagn Pathol       Date:  2022-02-10       Impact factor: 2.644

3.  Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report.

Authors:  Xueqian Wu; Weiya Wang; Bingwen Zou; Yanying Li; Xiaojuan Yang; Ning Liu; Qizhi Ma; Xiaoxuan Zhang; Yongsheng Wang; Dan Li
Journal:  Thorac Cancer       Date:  2020-03-24       Impact factor: 3.500

4.  A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib: A case report.

Authors:  Jun Guo; Junping Shi; Ming Yao; Yi Jin; Dengxiang Liu; Weiling Liu; Kai Wang; Da Jiang
Journal:  Medicine (Baltimore)       Date:  2020-11-06       Impact factor: 1.817
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.